Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4[beta]-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. - Ngaimisi, E; Minzi, O; Mugusi, S; Sasi, P; Riedel, K-D; Suda, A; Ueda, N; Bakari, M; Janabi, M; Mugusi, F; Bertilsson, L; Burhenne, J; et al. (Journal of Antimicrobial Chemotherapy (JAC), 2014)